Epigenetic modulation of PGC-1α activity by GCN5 inhibitors: WO2010007085

Author： Carradori Simone Secci Daniela Mai Antonello

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.10, 2011-10, pp. : 1651-1656

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting PGC-1α to control energy homeostasis

By Wu Zhidan Boss Olivier

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 10, 2007-10 ,pp. : 1329-1338

Informa Healthcare

Access to resources Recommend Favorite

The Role of PGC-1 in the Pathogenesis of Neurodegenerative Disorders

Current Drug Targets, Vol. 11, Iss. 10, 2010-10 ,pp. : 1262-1269

Bentham Science Publishers

Access to resources Recommend Favorite

Synthesis and Antiproliferative Activity of 3-aza Steroids as 5-reductase Inhibitors

Letters in Drug Design & Discovery, Vol. 14, Iss. 11, 2017-10 ,pp. : 1335-1346

Bentham Science Publishers

Access to resources Recommend Favorite

5-Lipoxygenase inhibitors: a patent evaluation (WO2011161615)

By Buscató Estel.la Proschak Ewgenij

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 7, 2012-07 ,pp. : 843-846

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012003387, Gilead's ASK1 inhibitors

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 4, 2012-04 ,pp. : 455-459

Informa Healthcare

Access to resources Recommend Favorite